How should I structure a case presentation for a 32‑year‑old male with severe hemophilia A, high‑titer inhibitor, on emicizumab prophylaxis, presenting with an acute left‑knee hemarthrosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Case Presentation: Severe Hemophilia A with High-Titer Inhibitor on Emicizumab Prophylaxis

Chief Complaint

32-year-old male with acute left knee hemarthrosis

History of Present Illness

  • Onset & Duration: [Specify when bleeding started, progression of symptoms]
  • Severity: Assess pain level (0-10), degree of swelling, functional limitation (inability to bear weight, range of motion restriction)
  • Precipitating factors: Recent trauma vs. spontaneous bleed
  • Prior similar episodes: Frequency of breakthrough bleeds on emicizumab, typical response to treatment
  • Home management attempted: Any factor replacement or bypassing agents used before presentation

Past Medical History

  • Hemophilia A: Severe (baseline FVIII <1%)
  • Inhibitor status: High-titer inhibitor (specify peak Bethesda units if known)
  • Current prophylaxis: Emicizumab [dose and frequency - typically 1.5 mg/kg weekly or 3 mg/kg every 2 weeks]
  • Baseline annualized bleeding rate (ABR) on emicizumab: [Document pre-emicizumab vs. current]
  • Joint status: Baseline arthropathy score, prior hemarthroses in affected joint
  • Inhibitor history: When developed, peak titer, any prior immune tolerance induction attempts

Current Medications

  • Emicizumab [specific dosing regimen]
  • [Any other medications]

Physical Examination

  • Vital signs: [Temperature, HR, BP - assess for hemodynamic instability]
  • Left knee examination:
    • Swelling: Measure circumference compared to contralateral knee
    • Warmth, erythema
    • Range of motion: Active and passive (degrees of flexion/extension)
    • Effusion: Ballottement test
    • Neurovascular status: Distal pulses, sensation, compartment assessment

Laboratory Data

  • Coagulation studies:
    • aPTT (will be prolonged but not interpretable on emicizumab)
    • FVIII activity (not reliable on emicizumab)
    • Inhibitor titer (current Bethesda units)
  • CBC: Hemoglobin/hematocrit (assess for significant blood loss)
  • Emicizumab level if available (though not routinely needed for acute management)

Imaging

  • Point-of-care ultrasound or MRI of left knee: Confirm hemarthrosis, assess volume, rule out compartment syndrome

Assessment

32-year-old male with severe hemophilia A, high-titer inhibitor, on emicizumab prophylaxis presenting with acute left knee hemarthrosis requiring bypassing agent therapy.

Management Plan

Acute Hemarthrosis Treatment

For this patient on emicizumab with breakthrough joint bleed, use recombinant factor VIIa (rFVIIa) as first-line bypassing agent 1, 2. The 2024 ISTH guidelines recommend either single-dose 270 μg/kg or three doses of 90 μg/kg at 3-hour intervals for joint bleeding 1.

Critical safety consideration: Avoid activated prothrombin complex concentrate (aPCC) in patients on emicizumab due to boxed warning for thrombotic microangiopathy and thrombosis risk 1, 3.

  • Initial dose: rFVIIa 90 μg/kg IV, repeat every 3 hours × 3 doses OR single dose 270 μg/kg
  • Adjunctive therapy: Tranexamic acid 10 mg/kg IV every 6-8 hours (safe with emicizumab) 4, 3
  • Joint management:
    • Rest, ice, compression, elevation (RICE protocol)
    • Consider arthrocentesis if tense hemarthrosis (>60 mL) to prevent chondrocyte apoptosis and chronic synovitis 5
    • Avoid weight-bearing until acute bleeding controlled

Monitoring

  • Clinical response: Pain reduction, decreased swelling, improved range of motion within 24-48 hours
  • Hemoglobin: Check at 24 hours if significant bleeding
  • Thrombotic surveillance: Given emicizumab + bypassing agent use, monitor for signs of thrombosis (though risk primarily with aPCC) 1, 6

Disposition

  • Admission criteria: Hemodynamically unstable, inadequate response to initial bypassing agent, need for repeated dosing, concern for compartment syndrome
  • Outpatient management: If bleeding controlled after initial treatment, close follow-up within 24-48 hours

Long-Term Considerations

  • Prophylaxis optimization: Assess emicizumab adherence and dosing adequacy. Current ABR on emicizumab should be near-zero 7. If recurrent breakthrough bleeds, consider:

    • Dose escalation (though not standard)
    • Evaluation for subclinical joint disease with imaging
    • Physical therapy for joint protection
  • Immune tolerance induction (ITI): Discuss with patient if not previously attempted, though success rate ~70% and burdensome 2

  • Future bleeding episodes: Patient education on early recognition and when to use bypassing agents at home vs. seeking emergency care

Follow-Up

  • Hemophilia treatment center visit within 1 week
  • Reassess joint status, consider physical therapy referral
  • Document breakthrough bleed in patient's bleeding log for ABR calculation

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.